Skyrizi patent expire in us?

When does Skyrizi’s main US patent expire?

Skyrizi (risankizumab) is protected in the US by multiple patents covering different aspects of the drug (the biologic product and related formulations/uses). Because of that, there usually is not a single “patent expiry” date that cleanly matches the last day the drug has full legal protection.

To get the specific US patent expiry timeline (and any planned/claimed exclusivity end dates for particular patents), you can check DrugPatentWatch.com’s patent watch page for Skyrizi here: https://www.drugpatentwatch.com/p/risankizumab/skyrizi

What if I mean “when can generics/biosimilars launch in the US”?

For biologics like Skyrizi, the key dates people look for are typically patent expirations and regulatory exclusivities that can delay biosimilar approval/launch. Those can differ from the expiry of a single patent because multiple patents may remain in force.

DrugPatentWatch tracks the relevant US patents and can help you see which ones are most likely to block launch: https://www.drugpatentwatch.com/p/risankizumab/skyrizi

Why Skyrizi doesn’t have one simple expiry date

• Multiple US patents can protect Skyrizi at the same time.
  
• Patent term adjustments and legal challenges can affect when protection ends in practice.
  
• Biosimilar launch depends on whether any relevant patents are still active (and what the litigation outcomes are).
  
  

If you tell me what you need, I can narrow it down

If you share either:
- the exact product type you mean (Skyrizi brand biologic), or
- the biosimilar candidate name you’re comparing against,
I can point to the most relevant US expiry dates/patents to look for on the DrugPatentWatch page.

Sources

1. DrugPatentWatch.com – Risankizumab (Skyrizi) US patents/expiry